Hemmo Pharmaceuticals is an API manufacturer based in India. It holds one active US drug master file across a filed portfolio of 2 molecules. Its filings concentrate with CDSCO (India) and MINSA (CR). Customs aggregates show $13.1M of exports covering 321 molecules to 40 destinations in 2022.
| Molecule | Regulators | Docs |
|---|---|---|
| Oxytocin | US FDA | 1 |
| Tetracosactide | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 1 | None |
| MINSA (CR) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2022 | Not reported | $13.1M | 40 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Hemmo Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.